0.36Open0.36Pre Close1 Volume0 Open Interest3.50Strike Price36.00Turnover1531.19%IV-1.95%PremiumDec 20, 2024Expiry Date0.42Intrinsic Value100Multiplier7DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.1586Delta0.0370Gamma1.21Leverage Ratio-0.1218Theta-0.0005Rho-0.19Eff Leverage0.0010Vega
Revance Therapeutics Stock Discussion
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
📊⚡️📊
No comment yet